168 related articles for article (PubMed ID: 35047056)
21. Gene Alterations of N6-Methyladenosine (m
Zhang Q; Cai Y; Kurbatov V; Khan SA; Lu L; Zhang Y; Johnson CH
Biomed Res Int; 2020; 2020():8826456. PubMed ID: 33415160
[TBL] [Abstract][Full Text] [Related]
22. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
23. Changes of N6-methyladenosine modulators promote breast cancer progression.
Wu L; Wu D; Ning J; Liu W; Zhang D
BMC Cancer; 2019 Apr; 19(1):326. PubMed ID: 30953473
[TBL] [Abstract][Full Text] [Related]
24. Potential role of m6A RNA methylation regulators in osteosarcoma and its clinical prognostic value.
Liu H; Qin G; Ji Y; Wang X; Bao H; Guan X; Wei A; Cai Z
J Orthop Surg Res; 2021 May; 16(1):294. PubMed ID: 33952279
[TBL] [Abstract][Full Text] [Related]
25. m6A RNA methylation regulators play an important role in the prognosis of patients with testicular germ cell tumor.
Cong R; Ji C; Zhang J; Zhang Q; Zhou X; Yao L; Luan J; Meng X; Song N
Transl Androl Urol; 2021 Feb; 10(2):662-679. PubMed ID: 33718069
[TBL] [Abstract][Full Text] [Related]
26. The Prognostic Value of m6A RNA Methylation Regulators in Colon Adenocarcinoma.
Liu T; Li C; Jin L; Li C; Wang L
Med Sci Monit; 2019 Dec; 25():9435-9445. PubMed ID: 31823961
[TBL] [Abstract][Full Text] [Related]
27. The pan-cancer analysis of the two types of uterine cancer uncovered clinical and prognostic associations with m6A RNA methylation regulators.
Zou Z; Zhou S; Liang G; Tang Z; Li K; Tan S; Zhang X; Zhu X
Mol Omics; 2021 Jun; 17(3):438-453. PubMed ID: 34110327
[TBL] [Abstract][Full Text] [Related]
28. N6-methyladenosine RNA methylation regulator-related alternative splicing gene signature as prognostic predictor and in immune microenvironment characterization of patients with low-grade glioma.
Maimaiti A; Tuersunniyazi A; Meng X; Pei Y; Ji W; Feng Z; Jiang L; Wang Z; Kasimu M; Wang Y; Shi X
Front Genet; 2022; 13():872186. PubMed ID: 35937991
[No Abstract] [Full Text] [Related]
29. Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.
Wu X; Zhang X; Tao L; Dai X; Chen P
Biomed Res Int; 2020; 2020():2053902. PubMed ID: 32733931
[TBL] [Abstract][Full Text] [Related]
30. m6A-Related Genes Contribute to Poor Prognosis of Hepatocellular Carcinoma.
Zou Y; Jiang G; Xie Y; Li H
Comput Math Methods Med; 2022; 2022():2427987. PubMed ID: 36339682
[TBL] [Abstract][Full Text] [Related]
31. Genetic analysis of N6-methyladenosine modification genes in Parkinson's disease.
Qin L; Min S; Shu L; Pan H; Zhong J; Guo J; Sun Q; Yan X; Chen C; Tang B; Xu Q
Neurobiol Aging; 2020 Sep; 93():143.e9-143.e13. PubMed ID: 32371107
[TBL] [Abstract][Full Text] [Related]
32. The role of m6A modification in the biological functions and diseases.
Jiang X; Liu B; Nie Z; Duan L; Xiong Q; Jin Z; Yang C; Chen Y
Signal Transduct Target Ther; 2021 Feb; 6(1):74. PubMed ID: 33611339
[TBL] [Abstract][Full Text] [Related]
33. M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT.
Huang GZ; Wu QQ; Zheng ZN; Shao TR; Chen YC; Zeng WS; Lv XZ
Aging (Albany NY); 2020 Jun; 12(12):11667-11684. PubMed ID: 32526707
[TBL] [Abstract][Full Text] [Related]
34. Contributions and Prognostic Values of N6-Methyladenosine RNA Methylation Regulators in Hepatocellular Carcinoma.
Qi LW; Jia JH; Jiang CH; Hu JM
Front Genet; 2020; 11():614566. PubMed ID: 33519919
[TBL] [Abstract][Full Text] [Related]
35. Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma.
Xu F; Guan Y; Ma Y; Xue L; Zhang P; Yang X; Chong T
Aging (Albany NY); 2021 Apr; 13(8):11919-11941. PubMed ID: 33952721
[TBL] [Abstract][Full Text] [Related]
36. The N6-methyladenosine methylation landscape stratifies breast cancer into two subtypes with distinct immunological characteristics.
Chen Y; Hou Y; Li S; Qin W; Zhang J
Clin Exp Pharmacol Physiol; 2024 Jul; 51(7):e13875. PubMed ID: 38797522
[TBL] [Abstract][Full Text] [Related]
37. Analysis of m6A-Related Signatures in the Tumor Immune Microenvironment and Identification of Clinical Prognostic Regulators in Adrenocortical Carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Hu X; Gong L; Xiao M; Chen X; Cheng Y; Cao K
Front Immunol; 2021; 12():637933. PubMed ID: 33746977
[TBL] [Abstract][Full Text] [Related]
38. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
Han X; Liu J; Cheng G; Cui S
Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
[TBL] [Abstract][Full Text] [Related]
39. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment.
Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J
BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861
[TBL] [Abstract][Full Text] [Related]
40. m6A RNA methylation regulators can contribute to malignant progression and impact the prognosis of bladder cancer.
Chen M; Nie ZY; Wen XH; Gao YH; Cao H; Zhang SF
Biosci Rep; 2019 Dec; 39(12):. PubMed ID: 31808521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
